Seattle Genetics achieves sales miletone under ADCETRIS collaboration Seattle Genetics announced that it will receive a $5M milestone payment under its ADCETRIS collaboration with Takeda Pharmaceutical Company Limited. The milestone was triggered by Takeda surpassing annual ADCETRIS net sales of $100M in its territories. The milestone will be recognized as royalty revenue in 1Q14. Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world. Seattle Genetics is entitled to royalties based on a percentage of Takeda's net sales in its territory at rates that range from the mid-teens to the mid-twenties based on sales volume, subject to offsets for royalties paid by Takeda to third parties. In addition, Seattle Genetics is entitled to receive progress- and sales-dependent milestone payments based on net sales of ADCETRIS within Takeda’s licensed territories. Seattle Genetics and Takeda are also funding joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs.